Oxford researchers will lead a \u00a32m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.
A pathway designed to investigate individuals with non-specific but concerning symptoms of cancer wins the BMJ Awards 2020 Cancer Care Team of the Year.
Prof. Anne Kiltie and her team discuss their important work into the effects of radiosensitisation on ageing cancer patients with the CRUK Science Blog.
Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient\u2019s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.
UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.
Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.
Congratulations to Prof Kristijan Ramadan who has been awarded a three year research grant from Breast Cancer Now. The grant will support Dr. Abhay Narayan Singh who will explore new ways to use chemotherapy in order to improve the outcomes for women with breast cancer.
Tuesday 4 Feb 2020 is World Cancer Day (https://www.worldcancerday.org/).\r\n\r\nLed by the Union for International Cancer Control, the day aims to raise awareness and education about cancer.
The NIHR has invested \u00a334 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).
Kristijan Ramadan and his group published a new article in The EMBO Journal today. The article adds new detail to the story of how our cells repair damage to our DNA.
The Department of Oncology has signed up to collaborate with Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics.
![\"A](\"https://www.oncology.ox.ac.uk/news/worlds-first-cancer-prevention-trial-to-test-diabetes-drug-in-patients-with-high-risk-genetic-condition/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n